Dave Dixon, PharmD, BCPS, CPP

Articles by Dave Dixon, PharmD, BCPS, CPP

Successful Collaborative Care Strategies for Pharmacists

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

May 28th 2024

The panel concludes its discussion with insights on successful strategies that can inform optimal collaborative care practices for cardiovascular risk reduction in patients with ASCVD.

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

May 14th 2024

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

May 14th 2024

The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.

Clinical Efficacy of Non-Statin Treatment Options in ASCVD

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

May 7th 2024

Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.

Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

May 7th 2024

Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.

Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

April 30th 2024

Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.

Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP,Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Dave Dixon, PharmD, BCPS, CPP

April 30th 2024

The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.

Stroke and TIAs- Minimizing the Risk of Recurrence

ByDave Dixon, PharmD, BCPS, CPP

December 28th 2009

Pharmacists can help reduce the number of recurrent strokes by counseling patients on the importance of adhering to their medication regimens and educating them about modifiable risk factors.